Cargando…
Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
BACKGROUND: The association between the development of checkpoint inhibitor pneumonitis (CIP) with tumor response and survival has remained unclear so far. The aim of the present study was to evaluate the association between CIP and the clinical efficacy of anti‐programmed cell death‐1 antibody in p...
Autores principales: | Ono, Kana, Ono, Hirotaka, Toi, Yukihiro, Sugisaka, Jun, Aso, Mari, Saito, Ryohei, Kawana, Sachiko, Aiba, Tomoiki, Odaka, Tetsuo, Matsuda, Suguru, Saito, Shin, Narumi, Akane, Ogasawara, Takahiro, Shimizu, Hisashi, Domeki, Yutaka, Terayama, Keisuke, Kawashima, Yosuke, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Honda, Yoshihiro, Sugawara, Shunichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290230/ https://www.ncbi.nlm.nih.gov/pubmed/34121358 http://dx.doi.org/10.1002/cam4.4045 |
Ejemplares similares
-
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
por: Sugisaka, Jun, et al.
Publicado: (2019) -
Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
por: Sugisaka, Jun, et al.
Publicado: (2023) -
Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers
por: Aiba, Tomoiki, et al.
Publicado: (2021) -
A Remarkable Clinical Response to Pembrolizumab in a Rare Spindle Cell Carcinoma of the Lung
por: Tsurumi, Kyoji, et al.
Publicado: (2019) -
Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
por: Isawa, Tsuyoshi, et al.
Publicado: (2022)